1
|
Cheeseman K, Ropars J, Renault P, Dupont J, Gouzy J, Branca A, Abraham AL, Ceppi M, Conseiller E, Debuchy R, Malagnac F, Goarin A, Silar P, Lacoste S, Sallet E, Bensimon A, Giraud T, Brygoo Y. Multiple recent horizontal transfers of a large genomic region in cheese making fungi. Nat Commun 2015; 5:2876. [PMID: 24407037 PMCID: PMC3896755 DOI: 10.1038/ncomms3876] [Citation(s) in RCA: 123] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Accepted: 11/06/2013] [Indexed: 02/01/2023] Open
Abstract
While the extent and impact of horizontal transfers in prokaryotes are widely acknowledged, their importance to the eukaryotic kingdom is unclear and thought by many to be anecdotal. Here we report multiple recent transfers of a huge genomic island between Penicillium spp. found in the food environment. Sequencing of the two leading filamentous fungi used in cheese making, P. roqueforti and P. camemberti, and comparison with the penicillin producer P. rubens reveals a 575 kb long genomic island in P. roqueforti—called Wallaby—present as identical fragments at non-homologous loci in P. camemberti and P. rubens. Wallaby is detected in Penicillium collections exclusively in strains from food environments. Wallaby encompasses about 250 predicted genes, some of which are probably involved in competition with microorganisms. The occurrence of multiple recent eukaryotic transfers in the food environment provides strong evidence for the importance of this understudied and probably underestimated phenomenon in eukaryotes. Horizontal gene transfers are known to play an important role in prokaryote evolution but their impact and prevalence in eukaryotes is less clear. Here, the authors sequence the genomes of cheese making fungi P. roqueforti and P. camemberti, and provide evidence for recent horizontal transfers of a large genomic region.
Collapse
Affiliation(s)
- Kevin Cheeseman
- INRA, UMR1319 Micalis, F-78352 Jouy-en-Josas, France; Genomic Vision, 80-84 rue des Meuniers, 92220 Bagneux, France; AgroParisTech, UMR Micalis, F-78352 Jouy-en-Josas, France
| | - Jeanne Ropars
- Origine, Structure, Evolution de la Biodiversité, UMR 7205 CNRS-MNHN, Muséum National d'Histoire Naturelle, CP39, 57 rue Cuvier, 75231 Paris Cedex 05, France; Univ Paris-Sud, Ecologie, Systématique et Evolution, UMR8079, 91405 Orsay, France; CNRS, Ecologie, Systématique et Evolution, UMR8079, 91405 Orsay, France
| | - Pierre Renault
- INRA, UMR1319 Micalis, F-78352 Jouy-en-Josas, France; AgroParisTech, UMR Micalis, F-78352 Jouy-en-Josas, France
| | - Joëlle Dupont
- Origine, Structure, Evolution de la Biodiversité, UMR 7205 CNRS-MNHN, Muséum National d'Histoire Naturelle, CP39, 57 rue Cuvier, 75231 Paris Cedex 05, France
| | - Jérôme Gouzy
- LIMP Toulouse, INRA/CNRS, INRA, 24 Chemin de Borde Rouge-Auzeville, CS 52627, 31326 Castanet-Tolosan Cedex, France; INRA, Laboratoire des Interactions Plantes-Microorganismes (LIPM), UMR441, F-31326 Castanet-Tolosan, France; CNRS, Laboratoire des Interactions Plantes-Microorganismes (LIPM), UMR2594, F-31326 Castanet-Tolosan, France
| | - Antoine Branca
- Univ Paris-Sud, Ecologie, Systématique et Evolution, UMR8079, 91405 Orsay, France; CNRS, Ecologie, Systématique et Evolution, UMR8079, 91405 Orsay, France
| | - Anne-Laure Abraham
- INRA, UMR1319 Micalis, F-78352 Jouy-en-Josas, France; AgroParisTech, UMR Micalis, F-78352 Jouy-en-Josas, France
| | - Maurizio Ceppi
- Genomic Vision, 80-84 rue des Meuniers, 92220 Bagneux, France
| | | | - Robert Debuchy
- Univ Paris-Sud, Institut de Génétique et Microbiologie, UMR8621, 91405 Orsay, France; CNRS, Institut de Génétique et Microbiologie UMR8621, 91405 Orsay, France
| | - Fabienne Malagnac
- Univ Paris-Sud, Institut de Génétique et Microbiologie, UMR8621, 91405 Orsay, France; Univ Paris Diderot, Sorbonne Paris Cité, Institut des Energies de Demain (IED), 75205 Paris, France
| | - Anne Goarin
- Univ Paris-Sud, Institut de Génétique et Microbiologie, UMR8621, 91405 Orsay, France
| | - Philippe Silar
- Univ Paris-Sud, Institut de Génétique et Microbiologie, UMR8621, 91405 Orsay, France; Univ Paris Diderot, Sorbonne Paris Cité, Institut des Energies de Demain (IED), 75205 Paris, France
| | - Sandrine Lacoste
- Origine, Structure, Evolution de la Biodiversité, UMR 7205 CNRS-MNHN, Muséum National d'Histoire Naturelle, CP39, 57 rue Cuvier, 75231 Paris Cedex 05, France
| | - Erika Sallet
- LIMP Toulouse, INRA/CNRS, INRA, 24 Chemin de Borde Rouge-Auzeville, CS 52627, 31326 Castanet-Tolosan Cedex, France; INRA, Laboratoire des Interactions Plantes-Microorganismes (LIPM), UMR441, F-31326 Castanet-Tolosan, France; CNRS, Laboratoire des Interactions Plantes-Microorganismes (LIPM), UMR2594, F-31326 Castanet-Tolosan, France
| | - Aaron Bensimon
- Genomic Vision, 80-84 rue des Meuniers, 92220 Bagneux, France
| | - Tatiana Giraud
- Univ Paris-Sud, Ecologie, Systématique et Evolution, UMR8079, 91405 Orsay, France; CNRS, Ecologie, Systématique et Evolution, UMR8079, 91405 Orsay, France
| | - Yves Brygoo
- 13 ruelle d'Aigrefoin 78470 St Rémy-lès-Chevreuse
| |
Collapse
|
2
|
Tessereau C, Buisson M, Monnet N, Imbert M, Barjhoux L, Schluth-Bolard C, Sanlaville D, Conseiller E, Ceppi M, Sinilnikova OM, Mazoyer S. Direct visualization of the highly polymorphic RNU2 locus in proximity to the BRCA1 gene. PLoS One 2013; 8:e76054. [PMID: 24146815 PMCID: PMC3795722 DOI: 10.1371/journal.pone.0076054] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Accepted: 08/17/2013] [Indexed: 01/15/2023] Open
Abstract
Although the breast cancer susceptibility gene BRCA1 is one of the most extensively characterized genetic loci, much less is known about its upstream variable number tandem repeat element, the RNU2 locus. RNU2 encodes the U2 small nuclear RNA, an essential splicing element, but this locus is missing from the human genome assembly due to the inherent difficulty in the assembly of repetitive sequences. To fill the gap between RNU2 and BRCA1, we have reconstructed the physical map of this region by re-examining genomic clone sequences of public databases, which allowed us to precisely localize the RNU2 array 124 kb telomeric to BRCA1. We measured by performing FISH analyses on combed DNA for the first time the exact number of repeats carried by each of the two alleles in 41 individuals and found a range of 6-82 copies and a level of heterozygosity of 98%. The precise localisation of the RNU2 locus in the genome reference assembly and the implementation of a new technical tool to study it will make the detailed exploration of this locus possible. This recently neglected macrosatellite could be valuable for evaluating the potential role of structural variations in disease due to its location next to a major cancer susceptibility gene.
Collapse
Affiliation(s)
- Chloé Tessereau
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
- Genomic Vision, Bagneux, Paris, France
| | - Monique Buisson
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
| | - Nastasia Monnet
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
| | - Marine Imbert
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
| | - Laure Barjhoux
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
| | - Caroline Schluth-Bolard
- Service de Génétique, Laboratoire de Cytogénétique Constitutionnelle, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon and CNRS UMR5292, Inserm U1028, Université Claude Bernard Lyon 1, Equipe TIGER, Lyon, France
| | - Damien Sanlaville
- Service de Génétique, Laboratoire de Cytogénétique Constitutionnelle, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon and CNRS UMR5292, Inserm U1028, Université Claude Bernard Lyon 1, Equipe TIGER, Lyon, France
| | | | | | - Olga M. Sinilnikova
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
- Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France
| | - Sylvie Mazoyer
- «Genetics of Breast Cancer» team, Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
- * E-mail:
| |
Collapse
|
3
|
Mokrani-Benhelli H, Gaillard L, Biasutto P, Le Guen T, Touzot F, Vasquez N, Komatsu J, Conseiller E, Pïcard C, Gluckman E, Francannet C, Fischer A, Durandy A, Soulier J, de Villartay JP, Cavazzana-Calvo M, Revy P. Primary microcephaly, impaired DNA replication, and genomic instability caused by compound heterozygous ATR mutations. Hum Mutat 2012; 34:374-84. [PMID: 23111928 DOI: 10.1002/humu.22245] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2012] [Accepted: 10/22/2012] [Indexed: 11/10/2022]
Abstract
Ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) kinases are two key regulators of DNA-damage responses (DDR) that are mainly activated in response to DNA double-strand breaks and single-stranded DNA damages, respectively. Seckel syndrome, a rare genetic disorder characterized by a microcephaly and a markedly reduced body size, has been associated with defective ATR-dependent DNA damage signaling. However, the only human genetic ATR defect reported so far is a hypomorphic splicing mutation identified in five related individuals with Seckel syndrome. Here, we report the first case of primary microcephaly with compound heterozygous mutations in ATR: a 540 kb genomic deletion on one allele and a missense mutation leading to splice dysregulation on the other, which ultimately lead to a sharp decrease in ATR expression. DNA combing technology revealed a profound spontaneous alteration of several DNA replication parameters in patient's cells and FISH analyses highlighted the genomic instability caused by ATR deficiency. Collectively, our results emphasize the crucial role for ATR in the control of DNA replication, and reinforce the complementary and nonredundant contributions of ATM and ATR in human cells to face DNA damages and warrant genome integrity.
Collapse
|
4
|
Cheeseman K, Rouleau E, Vannier A, Thomas A, Briaux A, Lefol C, Walrafen P, Bensimon A, Lidereau R, Conseiller E, Ceppi M. A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2. Hum Mutat 2012; 33:998-1009. [PMID: 22473970 DOI: 10.1002/humu.22060] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2011] [Accepted: 02/03/2012] [Indexed: 12/12/2022]
Abstract
The BRCA1 and BRCA2 genes are involved in breast and ovarian cancer susceptibility. About 2 to 4% of breast cancer patients with positive family history, negative for point mutations, can be expected to carry large rearrangements in one of these two genes. We developed a novel diagnostic genetic test for the physical mapping of large rearrangements, based on molecular combing (MC), a FISH-based technique for direct visualization of single DNA molecules at high resolution. We designed specific Genomic Morse Codes (GMCs), covering the exons, the noncoding regions, and large genomic portions flanking both genes. We validated our approach by testing 10 index cases with positive family history of breast cancer and 50 negative controls. Large rearrangements, corresponding to deletions and duplications with sizes ranging from 3 to 40 kb, were detected and characterized on both genes, including four novel mutations. The nature of all the identified mutations was confirmed by high-resolution array comparative genomic hybridization (aCGH) and breakpoints characterized by sequencing. The developed GMCs allowed to localize several tandem repeat duplications on both genes. We propose the developed genetic test as a valuable tool to screen large rearrangements in BRCA1 and BRCA2 to be combined in clinical settings with an assay capable of detecting small mutations.
Collapse
Affiliation(s)
- Kevin Cheeseman
- Genomic Vision, 80–84 rue des Meuniers,Bagneux, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ceppi M, Roleau E, Cheeseman K, Thomas A, Briaux A, Lefol C, Walrafen P, Bensimon A, Lidereau R, Conseiller E. P2-13-10: Detection, Visualization and High Resolution Physical Mapping of Large Rearrangements by Molecular Combing in the Hereditary Breast Cancer Genes BRCA1 and BRCA2. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The BRCA1 and BRCA2 genes are involved, with high penetrance, in breast and ovarian cancer susceptibility. About 2% to 4% of breast cancer patients with a positive family history who are negative for BRCA1 and BRCA2 point mutations can be expected to carry large genomic alterations (deletion or duplication) in one of the two genes, and especially BRCA1. However, large rearrangements are missed by direct sequencing.
Molecular Combing is a powerful FISH-based technique for direct visualization of single DNA molecules, allowing the entire genome to be examined at high resolution in a single analysis. We have developed a novel genetic test based on Molecular Combing. For that purpose, we designed specific BRCA1 and BRCA2 “Genomic Morse Codes” (GMC), also covering the non-coding regions and including large genomic portions flanking both genes. We developed a measurement strategy for the GMC signals, and validated our approach by blindly testing 10 breast cancer patients with a positive family history and 10 control patients. Large rearrangements, corresponding to deletions and duplications of one or several exons and with sizes ranging from 3 kb to 40 kb, were detected on both genes, including the characterization of 4 new mutations (for BRCA1: Del ex 3, Del ex 24 and Dup ex 3; for BRCA2: Dup ex 17–20). The identified mutations confirmed the results obtained with high-resolution zoom-in aCGH (11 k) in the same patients, with a resolution in the 1–2 kb range. Importantly, the developed GMC allowed to unambiguously localize several tandem repeat duplications on both genes, and to precisely map large rearrangements in the problematic Alu-rich 5'-region of BRCA1.
We propose the developed Molecular Combing genetic test as a valuable tool for the screening of tandem repeat duplications, CNVs, and other complex rearrangements in BRCA1 and BRCA2, such as translocations and inversions, to be combined in clinical settings with an essay that allows the detection of point mutations. We see the main application of the developed molecular diagnostic tool as a predictive genetic test. However, we envisage to extended the application of the developed tool as a companion diagnostic test, for instance in the screening of BRCA-mutated cells in the context of the development of PARP inhibitors. Thus, the genetic test may be applied not only to clinical blood samples, but also to circulating cells and heterogeneous cell populations, such as tumor tissues.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-13-10.
Collapse
Affiliation(s)
- M Ceppi
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - E Roleau
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - K Cheeseman
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - A Thomas
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - A Briaux
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - C Lefol
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - P Walrafen
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - A Bensimon
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - R Lidereau
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| | - E Conseiller
- 1Genomic Vision, Paris, France; Hôpital René Huguenin - Institut CURIE, Saint-Cloud, France
| |
Collapse
|
6
|
Kutschera S, Weber H, Weick A, De Smet F, Genove G, Takemoto M, Prahst C, Riedel M, Mikelis C, Baulande S, Champseix C, Kummerer P, Conseiller E, Multon MC, Heroult M, Bicknell R, Carmeliet P, Betsholtz C, Augustin HG. Differential Endothelial Transcriptomics Identifies Semaphorin 3G as a Vascular Class 3 Semaphorin. Arterioscler Thromb Vasc Biol 2011; 31:151-9. [DOI: 10.1161/atvbaha.110.215871] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Objective—
To characterize the role of a vascular-expressed class 3 semaphorin (semaphorin 3G [Sema3G]).
Methods and Results—
Semaphorins have been identified as axon guidance molecules. Yet, they have more recently also been characterized as attractive and repulsive regulators of angiogenesis. Through a transcriptomic screen, we identified Sema3G as a molecule of angiogenic endothelial cells. Sema3G-deficient mice are viable and exhibit no overt vascular phenotype. Yet, LacZ expression in the Sema3G locus revealed intense arterial vascular staining in the angiogenic vasculature, starting at E9.5, which was detectable throughout adolescence and downregulated in adult vasculature. Sema3G is expressed as a full-length 100-kDa secreted molecule that is processed by furin proteases to yield 95- and a 65-kDa Sema domain–containing subunits. Full-length Sema3G binds to NP2, whereas processed Sema3G binds to NP1 and NP2. Expression profiling and cellular experiments identified autocrine effects of Sema3G on endothelial cells and paracrine effects on smooth muscle cells.
Conclusion—
Although the mouse knockout phenotype suggests compensatory mechanisms, the experiments identify Sema3G as a primarily endothelial cell–expressed class 3 semaphorin that controls endothelial and smooth muscle cell functions in autocrine and paracrine manners, respectively.
Collapse
Affiliation(s)
- Simone Kutschera
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Holger Weber
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Anja Weick
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Frederik De Smet
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Guillem Genove
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Minoru Takemoto
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Claudia Prahst
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Maria Riedel
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Constantinos Mikelis
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Sylvain Baulande
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Catherine Champseix
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Petra Kummerer
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Emmanuel Conseiller
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Marie-Christine Multon
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Melanie Heroult
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Roy Bicknell
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Peter Carmeliet
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Christer Betsholtz
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| | - Hellmut G. Augustin
- From Vascular Oncology and Metastasis (S.K., A.W., C.P., M.R., C.M., M.H., and H.G.A.), German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany; Vascular Biology and Tumor Angiogenesis (S.K., A.W., C.P., M.H., and H.G.A.), Medical Faculty Mannheim (CBTM), Heidelberg University, Heidelberg, Germany; the Department of Vascular Biology and Angiogenesis Research (H.W., P.K., and H.G.A.), Tumor Biology Center, Freiburg, Germany; the Department for Transgene Technology and Gene
| |
Collapse
|
7
|
Rimmelé P, Komatsu J, Hupé P, Roulin C, Barillot E, Dutreix M, Conseiller E, Bensimon A, Moreau-Gachelin F, Guillouf C. Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. Cancer Res 2010; 70:6757-66. [PMID: 20660370 DOI: 10.1158/0008-5472.can-09-4691] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The multistage process of cancer formation is driven by the progressive acquisition of somatic mutations. Replication stress creates genomic instability in mammals. Using a well-defined multistep leukemia model driven by Spi-1/PU.1 overexpression in the mouse and Spi-1/PU.1-overexpressing human leukemic cells, we investigated the relationship between DNA replication and cancer progression. Here, using DNA molecular combing and flow cytometry methods, we show that Spi-1 increases the speed of replication by acting specifically on elongation rather than enhancing origin firing. This shortens the S-phase duration. Combining data from Spi-1 knockdown in murine cells with Spi-1 overexpression in human cells, we provide evidence that inappropriate Spi-1 expression is directly responsible for the replication alteration observed. Importantly, the acceleration of replication progression coincides with an increase in the frequency of genomic mutations without inducing DNA breakage. Thus, we propose that the hitherto unsuspected role for spi-1 oncogene in promoting replication elongation and genomic mutation promotes blastic progression during leukemic development.
Collapse
|
8
|
Gongora C, Candeil L, Vezzio N, Copois V, Denis V, Breil C, Molina F, Fraslon C, Conseiller E, Pau B, Martineau P, Del Rio M. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biol Ther 2008; 7:822-32. [PMID: 18340113 DOI: 10.4161/cbt.7.6.5838] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Irinotecan is a topoisomerase I inhibitor widely used as an anticancer agent in the treatment of metastatic colon cancer. However, its efficacy is often limited by the development of resistance. We have isolated a colon carcinoma cell line, HCT116-SN6, which displays a 6-fold higher resistance to SN38, the active metabolite of irinotecan. In this paper, we studied the molecular mechanisms that cause resistance to SN38 in the HCT116-SN6 cell line. First, we analyzed proliferation, cell cycle distribution, apoptosis, topoisomerase I expression and activity in SN38-resistant (HCT116-SN6) and sensitive (HCT116-s cells). We showed that the SN38-induced apoptosis and the SN38-activated cell cycle checkpoints leading to G(2)/M cell cycle arrest were similar in both cell lines. Topoisomerase I expression and catalytic activity were also unchanged. Then, we compared mRNA expression profiles in the two cell lines using the Affymetrix Human Genome GeneChip arrays U133A and B. Microarray analysis showed that among the genes, which were differentially expressed in HCT116-s and HCT116-SN6 cells, 27% were related to cell proliferation suggesting that proliferation might be the main target in the development of resistance to SN38. This result correlates with the phenotypic observation of a reduced growth rate in HCT116-SN6 resistant cells. Furthermore, 29% of the overexpressed genes were Interferon Stimulated Genes and we demonstrate that their overexpression is, at least partially, due to endogenous activation of the p38 MAP kinase pathway in SN38 resistant cells. In conclusion, a slower cell proliferation rate may be a major cause of acquired resistance to SN38 via a reduction of cell cycle progression through the S phase which is mandatory for the cytotoxic action of SN38. This lower growth rate could be due to the endogenous activation of p38.
Collapse
|
9
|
Vié N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C, Martineau P, Del Rio M, Gongora C. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008; 7:14. [PMID: 18221502 PMCID: PMC2245978 DOI: 10.1186/1476-4598-7-14] [Citation(s) in RCA: 112] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2007] [Accepted: 01/25/2008] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Colorectal cancer (CRC) is one of the most common causes of cancer death throughout the world. In this work our aim was to study the role of the phosphoserine aminotransferase PSAT1 in colorectal cancer development. RESULTS We first observed that PSAT1 is overexpressed in colon tumors. In addition, we showed that after drug treatment, PSAT1 expression level in hepatic metastases increased in non responder and decreased in responder patients. In experiments using human cell lines, we showed that ectopic PSAT1 overexpression in colon carcinoma SW480 cell line resulted in an increase in its growth rate and survival. In addition, SW480-PSAT1 cells presented a higher tumorigenic potential than SW480 control cells in xenografted mice. Moreover, the SW480-PSAT1 cell line was more resistant to oxaliplatin treatment than the non-transfected SW480 cell line. This resistance resulted from a decrease in the apoptotic response and in the mitotic catastrophes induced by the drug treatment. CONCLUSION These results show that an enzyme playing a role in the L-serine biosynthesis could be implicated in colon cancer progression and chemoresistance and indicate that PSAT1 represents a new interesting target for CRC therapy.
Collapse
Affiliation(s)
- Nadia Vié
- CNRS, UMR 5160, CRLC, 15, av, Charles Flahault, BP14491, 34093, Montpellier Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007; 25:773-80. [PMID: 17327601 PMCID: PMC2257989 DOI: 10.1200/jco.2006.07.4187] [Citation(s) in RCA: 140] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this regimen, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed to identify a gene expression profile in primary colon cancer tissue that could predict chemotherapy response. PATIENTS AND METHODS Tumor colon samples from 21 patients with advanced colorectal cancer were analyzed for gene expression profiling using Human Genome GeneChip arrays U133. At the end of the first-line treatment, the best observed response, according to WHO criteria, was used to define the responders and nonresponders. Discriminatory genes were first selected by the significance analysis of microarrays algorithm and the area under the receiver operating characteristic curve. A predictor classifier was then constructed using support vector machines. Finally, leave-one-out cross validation was used to estimate the performance and the accuracy of the output class prediction rule. RESULTS We determined a set of 14 predictor genes of response to FOLFIRI. Nine of nine responders (100% specificity) and 11 of 12 nonresponders (92% sensitivity) were classified correctly, for an overall accuracy of 95%. CONCLUSION After validation in an independent cohort of patients, our gene signature could be used as a decision tool to assist oncologists in selecting colorectal cancer patients who could benefit from FOLFIRI chemotherapy, both in the adjuvant and the first-line metastatic setting.
Collapse
Affiliation(s)
- Maguy Del Rio
- Centre National de la Recherche Scientifique Unité Mixte de Recherche 5160, Service d'Anatomie pathologique, Service d'Oncologie Digestive, Montpellier, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ottenschlager I, Epstein C, Delaisi C, Fraslon C, Conseiller E, Long H, Viviani F, Combeau C, Bissery M, Casellas P. 287 POSTER Characterizati on of alvocidib (flavopiridol)-mediated inhibition of CDK enzyme activity and the down-regulation of gene transcription. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)70292-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
12
|
Copois V, Bibeau F, Bascoul-Mollevi C, Salvetat N, Chalbos P, Bareil C, Candeil L, Fraslon C, Conseiller E, Granci V, Mazière P, Kramar A, Ychou M, Pau B, Martineau P, Molina F, Del Rio M. Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol 2006; 127:549-59. [PMID: 16945445 DOI: 10.1016/j.jbiotec.2006.07.032] [Citation(s) in RCA: 143] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2006] [Revised: 07/21/2006] [Accepted: 07/27/2006] [Indexed: 11/24/2022]
Abstract
DNA microarray technology enables investigators to measure the expression of several 1000 mRNA species simultaneously in a biological specimen. However, the reliability of the microarray technology to detect transcriptional differences representative of the original samples is affected by the quality of the extracted RNA. Thus, it is of critical importance to standardize sample-handling protocols and to perform a quality assessment of RNA preparations. In this report, 59 human tissue samples were used to evaluate the relationships between RNA quality and gene expression. From Affymetrix GeneChip array data analysis of these samples, we compared the performance of the 28S/18S ratio, two computer methods (RIN and degradometer) and our in-house RNA quality scale (RQS) in assessing RNA quality. The optimal RNA reliability threshold was determined for each method using statistical discrimination measures. We showed that RQS, RIN and degradometer have a similar capacity to detect reliable RNA samples whereas the 28S/18S ratio leads to a misleading categorization. Furthermore, we developed a new approach, based on clustering analyses of full chip expression, to control RNA quality after hybridization experiments. The combination of these methods, allowing monitoring of RNA quality prior to and after the hybridization experiments, ensured reliable and reproducible microarray data.
Collapse
|
13
|
Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M, Weller M. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res 2001; 61:5833-42. [PMID: 11479223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Adenoviral chimeric tumor suppressor 1 (CTS1) gene transfer was evaluated as a novel approach of somatic gene therapy for malignant glioma. CTS1 is an artificial p53-based gene designed to resist various pathways of p53 inactivation. Here, we report that an adenovirus encoding CTS1 (Ad-CTS1) induces growth arrest and loss of viability in all glioma cell lines examined, in the absence of specific cell cycle changes. In contrast, an adenovirus encoding wild-type p53 (Ad-p53) does not consistently induce apoptosis in the same cell lines. Electron microscopic analysis of Ad-CTS1-infected glioma cells reveals complex cytoplasmic pathology and delayed apoptotic changes. Ad-CTS1 induces prominent activation of various p53 target genes, including p21 and MDM-2, but has no relevant effects on BCL-2 family protein expression. Although Ad-CTS1 strongly enhances CD95 expression at the cell surface, endogenous CD95/CD95 ligand interactions do not mediate CTS1-induced cell death. This is because Ad-CTS1 promotes neither caspase activation nor mitochondrial cytochrome c release and because the caspase inhibitors, z-val-Ala-DL-Asp-fluoromethylketone (zVAD)-fmk or z-Ile-Glu-Thr-Asp- fluoromethylketone (z-IETD)-fmk, do not block CTS1-induced cell death. Ad-CTS1 synergizes with radiotherapy and CD95 ligand in killing glioma cells. In summary, Ad-CTS1 induces an unusual type of cell death that appears to be independent of BCL-2 family proteins, cytochrome c release, and caspases. CTS1 gene transfer is a promising strategy of somatic gene therapy for malignant glioma.
Collapse
Affiliation(s)
- U Naumann
- Laboratory of Molecular Neuro-Oncology, Department of Neurology, Institute of Pathology, University of Tübingen Medical School, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Gallagher WM, Greene LM, Ryan MP, Sierra V, Berger A, Laurent-Puig P, Conseiller E. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett 2001; 489:59-66. [PMID: 11231014 DOI: 10.1016/s0014-5793(00)02389-9] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Here, we report the identification of a human orthologue of fibulin-4, along with analysis of its biosynthetic processing and mRNA expression levels in normal and tumour tissues. Comparative sequence analysis of fibulin-4 cDNAs revealed apparent polymorphisms in the signal sequence that could account for previously reported inefficient secretion in fibulin-4 transfectants. In vitro translation of fibulin-4 mRNA revealed the presence of full-length and truncated polypeptides, the latter apparently generated from an alternative translation initiation site. Since this polypeptide failed to incorporate into endoplasmic reticulum membrane preparations, it was concluded that it lacked a signal sequence and thus could represent an intracellular form of fibulin-4. Using fluorescence in situ hybridisation analysis, the human fibulin-4 gene was localised to chromosome 11q13, this region being syntenic to portions of mouse chromosomes 7 and 19. Considering the fact that translocations, amplifications and other rearrangements of the 11q13 region are associated with a variety of human cancers, the expression of human fibulin-4 was evaluated in a series of colon tumours. Reverse transcription-polymerase chain reaction analysis of RNA from paired human colon tumour and adjacent normal tissue biopsies showed that a significant proportion of tumours had approximately 2-7-fold increases in the level of fibulin-4 mRNA expression. Taken together, results reported here suggest that an intracellular form of fibulin-4 protein may exist and that dysregulated expression of the fibulin-4 gene is associated with human colon tumourigenesis.
Collapse
Affiliation(s)
- W M Gallagher
- Conway Institute of Biomolecular and Biomedical Research, Department of Pharmacology, University College Dublin, Belfield, Ireland.
| | | | | | | | | | | | | |
Collapse
|
15
|
Gallagher WM, Argentini M, Sierra V, Bracco L, Debussche L, Conseiller E. MBP1: a novel mutant p53-specific protein partner with oncogenic properties. Oncogene 1999; 18:3608-16. [PMID: 10380882 DOI: 10.1038/sj.onc.1202937] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Using a yeast two-hybrid screening strategy with a common tumour-derived p53 mutant as bait, we identified several mutant p53-interacting partners including the known proteins wild-type (wt) p53, hUBC9 and GBP/PIAS1. In addition, a novel protein partner was identified which we have termed MBP1, for Mutant p53-Binding Protein 1. MBP1 is a new member of the emerging fibulin gene family, which currently comprises fibulin-1, fibulin-2 and S1-5. Expression of MBP1 mRNA is differentially regulated both temporally during development of the mouse embryo and in a tissue-specific manner within the adult. Specific interaction between MBP1 and mutant p53 was illustrated by both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells. MBP1 displayed the following order of binding specificity towards different p53 forms: H175 > G281 > H273 > or = W248>wt p53. Thus, MBP1 appears to bind preferentially to p53 mutants of the 'structural' rather than 'contact' class, reflecting a potential bias towards those mutants having a significant alteration in conformation from that assumed by wt p53. We propose that MBP1 is the product of a candidate oncogene as rates of both neoplastic transformation and tumour cell growth were shown to be significantly enhanced when the protein is ectopically overexpressed. Furthermore, MBP1 may play a role in determining if a 'gain of function' effect is seen with certain p53 mutants.
Collapse
Affiliation(s)
- W M Gallagher
- Oncology Department, Rhône-Poulenc Rorer, CRVA, Vitry-sur-Seine, France
| | | | | | | | | | | |
Collapse
|
16
|
Venot C, Maratrat M, Sierra V, Conseiller E, Debussche L. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. Oncogene 1999; 18:2405-10. [PMID: 10327062 DOI: 10.1038/sj.onc.1202539] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The wild-type protein product of the p53 tumor suppressor gene can activate transcription of genes which are involved in mediating either growth arrest, e.g. WAF1 or apoptotis, e.g. BAX and PICG3. Additionally, p53 can repress a variety of promoters, which, in turn, may be responsible for the functional activities exhibited by p53. This study shows that the Q22, S23 double mutation, which is known to inactivate a p53 transactivation subdomain located within the initial 40 residues of the protein, while abrogating transactivation from the WAF1 promoter, only attenuates apoptosis triggering, transactivation from other p53-responsive promoters and repression of promoters by p53. The Q53, S54 double mutation, which inactivates another p53 transactivation subdomain situated between amino acids 43 and 73 results in attenuation of all of the aforementioned p53 activities. In contrast to the Q22, S23 double mutation, this latter mutation set does not alter mdm-2-mediated inhibition and degradation of p53. Finally, mutation of all four residues results in complete abrogation of every p53 activity mentioned above.
Collapse
Affiliation(s)
- C Venot
- Centre de Recherche de Vitry-Alfortville, Rhône-Poulenc Rorer, Vitry sur Seine, France
| | | | | | | | | |
Collapse
|
17
|
Mary MN, Venot C, Caron de Fromentel C, Debussche L, Conseiller E, Cochet O, Gruel N, Teillaud JL, Schweighoffer F, Tocque B, Bracco L. A tumor specific single chain antibody dependent gene expression system. Oncogene 1999; 18:559-64. [PMID: 9927213 DOI: 10.1038/sj.onc.1202377] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The design of conditional gene expression systems restricted to given tissues or cellular types is an important issue of gene therapy. Systems based on the targeting of molecules characteristic of the pathological state of tissues would be of interest. We have developed a synthetic transcription factor by fusing a single chain antibody (scFv) directed against p53 with the bacterial tetracycline repressor as a DNA binding domain. This hybrid protein binds to p53 and can interact with a synthetic promoter containing tetracycline-operator sequences. Gene expression can now be specifically achieved in tumor cells harboring an endogenous mutant p53 but not in a wild-type p53 containing tumor cell line or in a non-transformed cell line. Thus, a functional transactivator centered on single chain antibodies can be expressed intracellularly and induce gene expression in a scFv-mediated specific manner. This novel class of transcriptional transactivators could be referred as 'trabodies' for transcription-activating-antibodies. The trabodies technology could be useful to any cell type in which a disease related protein could be the target of specific antibodies.
Collapse
Affiliation(s)
- M N Mary
- Gene Medicine Department, Rhône-Poulenc Rorer S.A., Vitry-sur-Seine, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 1999; 18:551-7. [PMID: 9927212 DOI: 10.1038/sj.onc.1202338] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We report here the production and the properties of single chain Fv fragments (scFvs) derived from the anti-p53 monoclonal antibodies PAb421 and 11D3. 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421. The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53 -/-human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present. Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53 -/- human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant deficient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.
Collapse
|
19
|
Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 1998; 17:4668-79. [PMID: 9707426 PMCID: PMC1170796 DOI: 10.1093/emboj/17.16.4668] [Citation(s) in RCA: 231] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Wild-type p53 is a tumor suppressor gene which can activate or repress transcription, as well as induce apoptosis. The human p53 proline-rich domain localized between amino acids 64 and 92 has been reported to be necessary for efficient growth suppression. This study shows that this property mainly results from impaired apoptotic activity. Although deletion of the proline-rich domain does not affect transactivation of several promoters, such as WAF1, MDM2 and BAX, it does alter transcriptional repression, reactive oxygen species production and sequence-specific transactivation of the PIG3 gene, and these are activities which affect apoptosis. Whereas gel retardation assays revealed that this domain did not alter in vitro the specific binding to the p53-responsive element of PIG3, this domain plays a critical role in transactivation from a synthetic promoter containing this element. To explain this discrepancy, evidence is given for a proline-rich domain-mediated cellular activation of p53 DNA binding.
Collapse
Affiliation(s)
- C Venot
- Centre de Recherche de Vitry-Alfortville, Rhône-Poulenc Rorer, 13 quai Jules Guesde, 94403 Vitry sur Seine Cedex, France
| | | | | | | | | | | |
Collapse
|
20
|
Conseiller E, Debussche L, Landais D, Venot C, Maratrat M, Sierra V, Tocque B, Bracco L. CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest 1998; 101:120-7. [PMID: 9421473 PMCID: PMC508547 DOI: 10.1172/jci1140] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The clinical potential of the p53 tumor suppressor gene is being evaluated currently for gene therapy of cancer. We have built a variant of wild-type p53, chimeric tumor suppressor 1 (CTS1), in which we have replaced the domains that mediate its inactivation. CTS1 presents some very interesting properties: (a) enhanced transcriptional activity; (b) resistance to the inactivation by oncogenic forms of p53; (c) resistance to the inactivation by MDM2; (d) lower sensitivity to E6-induced degradation; (e) ability to suppress cell growth; and (f ) faster induction of apoptosis. Thus, CTS1 is an improved tumor suppressor and an alternative for the treatment of wild-type p53-resistant human tumors by gene therapy.
Collapse
Affiliation(s)
- E Conseiller
- Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France
| | | | | | | | | | | | | | | |
Collapse
|